FIA
CRSP icon

FNY Investment Advisers’s CRISPR Therapeutics CRSP Stock Holding History

FNY Investment Advisers’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-105
Closed -$4K – 766
2024
Q4 		$4K Buy
+105
New +$4.96K ﹤0.01% 547

Other funds holding CRSP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Swiss National Bank
Swiss National Bank Zurich, Switzerland $191B AUM 45.21% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

FNY Investment Advisers's CRSP Position: Q2 2026 in Review

FNY Investment Advisers opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 10 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #895 among its holdings. This is a return to the name: FNY Investment Advisers previously reported a position in CRSP as recently as Q4 2024.

FNY Investment Advisers first reported a position in CRSP in Q1 2021 and has held it in 5 quarters since. The position peaked at $413K in Q4 2024. 308 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • FNY Investment Advisers held 10 shares of CRISPR Therapeutics worth $0 as of Q2 2026.
  • CRISPR Therapeutics was a new FNY Investment Advisers position in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of FNY Investment Advisers's portfolio in Q2 2026, its #895 holding.
  • FNY Investment Advisers first reported a position in CRISPR Therapeutics in Q1 2021 and has held it in 5 quarters since.
  • FNY Investment Advisers's CRISPR Therapeutics position peaked at $413K in Q4 2024.
  • 308 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on FNY Investment Advisers's 13F filing for Q2 2026, filed 8 Jul 2026.